SHANGHAI, Nov. 4, 2024 /PRNewswire/ — BioCity Biopharma (BioCity) announced late-breaking results of the 2-SUCCEED clinical trial of SC0062, a selective endothelin receptor type A (ETA) antagonist, for the treatment of IgA Nephropathy (IgAN). These […]
#Rosal Top Picks
Recent Posts
- Revenues and Operating Income: For the three months
- ABU DHABI, VAE, 14. November 2025 /PRNewswire/ —
- Pro Gamers and UFC Athletes Battle It Out Aboard the
- Attribute Heating, Cooling, Plumbing & Electrical
- ST. LOUIS, Nov. 14, 2025 /PRNewswire/ — Spire
